DXR · Daxor Corporation

-

Please sign in to comment on DXR

1 Comment

Admin

4 years, 10 months ago

Daxor Corporation is currently in a long term downtrend where the price is trading 13.1% below its 200 day moving average.

From a valuation standpoint, the stock is 990.0% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 98.8.

Daxor Corporation's total revenue sank by 22.3% to $145K since the same quarter in the previous year.

Its net income has increased by 297.8% to $2M since the same quarter in the previous year.

Finally, its free cash flow fell by 118.2% to $-555K since the same quarter in the previous year.

Based on the above factors, Daxor Corporation gets an overall score of 1/5.

ISIN	US2394671034
Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Medical Instruments & Supplies

Beta	0.03
Market Cap	72M
PE Ratio	77.19
Target Price	22.5
Dividend Yield	None

ABOUT

Daxor Corporation

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

DXR · Daxor Corporation

-

Daxor Corporation

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Daxor Corporation using a moving average strategy